Search Videos and More
Document
Tip Sheet: Laboratory Monitoring for Patients on Oral Chemotherapy or Oral Targeted Therapies
The Breast Oncology Center developed this reference for providers on lab monitoring for patients on oral chemotherapy or oral targeted therapies in November 2025.
Course
3rd Annual Lynch Syndrome Scientific Symposium
The 3rd Annual Lynch Syndrome Scientific Symposium will be held on Monday, April 13 at Hotel Commonwealth in Boston, MA. This symposium is dedicated to researchers and clinicians focused on the study and clinical care of individuals with Lynch syndrome. We will be accepting abstracts on Lynch syndrome research and relevant case reports. The deadline to submit an abstract is February 16, 2026 at 11:59PM EST.
News
Dana-Farber Research News 01.15.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from December 16 - 31.
Symposium
Breast Cancer Breakthroughs: ESMO 2025 Highlights
Experts in Dana-Farber’s Breast Oncology Center discuss highlights in breast cancer research innovation presented at ESMO25 in Berlin, Germany, including what the data means, how it can be used in clinic, and what’s next in the field of breast cancer research.
News
Dr. Mariella Filbin Receives 2026 Emerging Leader Award from The Mark Foundation
he Mark Foundation for Cancer Research has named Dr. Mariella Filbin, Research Co-Director of the Pediatric Neuro-Oncology Program at Dana-Farber Cancer Institute, the recipient of the 2026 Emerging Leader Award, recognizing her innovative work to advance treatment options for aggressive childhood brain tumors.
News
Seeing Is Believing
How Technicolor Images of Tumor Samples Are Changing Cancer Research
News
Dana-Farber Researchers Discover How Major Nuclear Protein Complexes Control Specialized Gene Regulation in Cancer and Beyond
The SWI/SNF Ig-Fold for Transcription Factor Interactions or ‘SWIFT’ domain on mSWI/SNF chromatin remodeling complexes engage proteins called transcription factors (TFs) to target specialized genes along human DNA—often cancer-promoting genes—flagging SWIFT-TF interactions as promising new therapeutic targets.
News
Dana-Farber Research News 01.01.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from December 1 - 15.
Video
Jennifer Brown, MD, PhD discusses results form the ALPINE trial
Symptom-based progression-free survival (S-PFS) as a clinically relevant and patient-centric endpoint in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
Video
Austin Kim, MD discusses phase I/II study
Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)
Video
Marlise Luskin, MD, MSCE discusses results of a phase 1 trial
Venetoclax plus inotuzumab ozogramicin for relapsed and refractory ALL: Results of a phase 1 trial
Video
Maria Capilla Guerra, MD discusses rapid diagnosis of acute leukemia with integrated epigentic and genetic profiling